A real world study assessing the treatment patterns and survival outcomes for patients with stage III vs IV Non-small cell lung cancer previously treated with platinum and immunotherapy
Latest Information Update: 30 May 2022
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 May 2022 New trial record
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research